Cutaneous Oncology News

Findings from a comprehensive systematic review and meta-analysis showed a “negligible” risk for melanoma among individuals treated with methotrexate.

CHICAGO — OCT accurately staged skin cancers, allowing for better diagnosis of basal cell carcinoma, prediction of margins and improved planning for Mohs surgery, according to a study presented here.

An experimental test may help predict which patients with cancer may develop disease recurrence after immunotherapy treatment, according to study results published in Clinical Cancer Research.

MILAN — Patients who underwent re-excision for positive margins after incomplete surgery for basal cell carcinoma had significantly lower recurrence rates than those who were followed up clinically, according to a poster presented here.

Adjuvant nivolumab extended RFS compared with placebo among patients with stage IIB/stage IIC melanoma, according to topline data released by the agent’s manufacturer.

An off-the-shelf T-cell receptor therapy has shown promising early results in multiple solid tumor types, according to initial data from a phase 1 dose-escalation trial presented at ESMO Congress.

FDA issued a safety alert Thursday regarding reports of squamous cell carcinoma and various lymphomas in the scar tissue surrounding breast implants.

A recent comparative analysis shed light on the differences between subcutaneous panniculitis-like T-cell lymphoma and the similar adipotropic lymphoproliferative disorder, according to a study.

Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year survival than controls, according to data.

Dermatopathologists were often influenced by prior diagnoses when giving second opinions, especially in challenging cases, according to a study.